Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Data Collection × NET × Clear all

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 11 Gastrointestinal 10 Other hematologic neoplasm 6 Gynecologic 6 Lymphoid 5 Genitourinary 5 Breast 5 Thoracic 4 Head & Neck 4 Dermatologic 4 Plasma cell 3 Sarcoma 2 Other solid neoplasm 2 Classical hematology 2 NET 1 Myeloid 1 Endocrine 1 CNS 1

Conditions

Intestinal Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 29 Everolimus 17 Magnetic Resonance Spectroscopy 13 gallium Ga 68 dotatate 10 Temozolomide 9 Nivolumab 9 Capecitabine 9 177Lu-octreotide, DOTA(0)-Tyr(3)- 8 lanreotide 7 Positron Emission Tomography Computed Tomography 7 Somatostatin 6 Octreotide 6 90Y-octreotide, DOTA-Tyr(3)- 6 pembrolizumab 5 cabozantinib 5 Lutetium-177 5 Fluorodeoxyglucose F18 5 3-Iodobenzylguanidine 5 pasireotide 4 avelumab 4 Ipilimumab 4 Ga(III)-DOTATOC 4 Carboplatin 4 Al18F-NOTA-octreotide 4 telotristat ethyl 3 surufatinib 3 fluorodopa F 18 3 copper dotatate CU-64 3 Surveys and Questionnaires 3 Single Photon Emission Computed Tomography Computed Tomography 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06876532 2025-11-18

LUTIBI

Institut Claudius Regaud

Phase NA Recruiting

Intestinal Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡